厄贝沙坦治疗缺血性心肌病临床评价  

The Assessment of Irbesartan in Treating Ischemic Cardlomyopathy

作　　者：王海涛[1] 王新民[1] 袁阳[1] 

机构地区：[1]解放军107医院急救中心,山东省烟台市264002

出　　处：《医学理论与实践》2002年第5期504-505,共2页The Journal of Medical Theory and Practice

摘　　要：目的:评价厄贝沙坦治疗缺血性心肌病心力衰竭的临床疗效。方法:缺血性心肌病病人随机分为治疗组和对照组,其中治疗组22例(厄贝沙坦150mg,qd,PO,加常规处理),对照组20例(常规处理)。详细记录入院时和治疗4周临床症状体征、心脏彩超左室射血分数(LVEF)值及药物不良反应,观察治疗4周心功能恢复情况。结果:治疗组临床心功能改善程度较对照组大(P<0.01),治疗组LVEF改善较对照级更明显(P<0.01),两组均无咳嗽及其他显著不良反应发生。结论:厄贝沙坦能够明显改善缺血性心肌病患者心功能,可明显提高LVEF,不良反应少。Objective:To evaluate the effect of irbesartan in treating ischemic cardiomyopathy.Methods:42 patients with ischemic cardiomyopathy were randomly divided into two groups. 20 patients were admitted to conventional treatment group (control group) ,and the treatment group involved 22 patients who were given irbesartan orally 150mg a day for 4 weeks besides conventionl treatment. Re-Sults:In improving cardiac function and LVEF,treatment group was more obvious than control group (P < 0.01) .There was no obviously adverse reaction found. Conclusion: Irbesartan is a kind of effective medicine which is fit for the treatment of ischemic cardiomyopathy with CHF.

关 键 词：厄贝沙坦 治疗 缺血性心肌病 临床评价 

分 类 号：R542.205[医药卫生—心血管疾病]